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Transplant recipients receive potent immunosuppressive drugs in order to prevent
graft rejection. Therapeutic drug monitoring is the current approach to guide the
dosing of calcineurin inhibitors, mammalian target of rapamycin inhibitors (mTORi)
and mofetil mycophenolate. Target concentrations used in pediatric patients are
extrapolated from adult studies. Gene polymorphisms in metabolizing enzymes and drug
transporters such as cytochromes CYP3A4 and CYP3A5, UDP-glucuronosyl transferase,
and P-glycoprotein are known to influence the pharmacokinetics and dose requirements
of immunosuppressants. The implications of pharmacogenomics in this patient population
is discussed. Genetic information can help with achieving target concentrations in the
early post-transplant period, avoiding adverse drug reactions and drug-drug interactions.
Evidence about genetic studies and transplant outcomes is revised.
Keywords: pharmacogenomics, genotype, adverse reactions, immunosuppression, drug metabolism, acute
rejection, graft survival, GWAS
RENAL TRANSPLANTATION IN CHILDREN
Renal transplant is a rational therapeutic option for children with
end stage renal disease (Dharnidharka et al., 2014). The success
of transplant has improved in the past decades, mainly due to the
use of potent immunosuppressive regimes to prevent graft rejec-
tion (Hartono et al., 2013). From 1980 to 2012 the first year acute
rejection rate has declined from 80 to 10–15% (Dharnidharka
et al., 2014).
As depicted in Table 1, there are several differences between
pediatric and adult renal transplant recipients. The leading cause
of kidney failure in children is congenital abnormalities of the
kidney and urinary tract (CAKUT) whereas in adults the main
causes are diabetes and hypertension. Consequently, perioper-
ative and long-term care differ between children and adults.
Age-related changes in the immune system can impact antigen
presentation and immune response to the allograft. For exam-
ple, variation in thymic response is especially important in young
children, as the thymus undergoes involution with advancing
age (Linton and Dorshkind, 2004; Dorshkind and Swain, 2009).
Moreover, T cells are naïve in children, and have reduced expres-
sion of CD40L (Brugnoni et al., 1996). CD4+ T cells subsets are
primarily defined as their ability to produce interferon gamma
(IFN-γ) and IL4 as T helper 1 (Th1) or Th2, in a study eval-
uating age dependant CD4+ T cell responses upon stimulation
with staphylococcal enterotoxin, it was noted that the frequency
of activated T cells that produce IFN-γ remained lower than
adults until 10 years of age, meaning a tendency for Th2 response
(Dorshkind et al., 2009; Hanna-Wakim et al., 2009). Age-related
changes in pharmacokinetics have been described, as the absorp-
tion, distribution, metabolism and excretion of drugs change
with age. Infants generally have a higher metabolic capacity and
may require higher doses or reduced dosing intervals for many
drugs, and the toxicity profile can also be different (Kearns
et al., 2003; Sage et al., 2014). A major hepatic enzyme involved
in drug biotransformation at birth is CYP3A7 and its expres-
sion declines during the first 6 months of life, whereas CYP3A4
reaches adult levels after 1 year of age (Hines, 2008). In addi-
tion, the risk of viral infectious disease and related complications
post-transplant change with age, since young children are less
likely to be exposed to certain viruses such as Epstein-Barr virus,
Cytomegalovirus and BK virus, and if acquiring a primary infec-
tion after transplant, the outcome can be worse (Dharnidharka
et al., 2014). Comparing 10-year transplant survival by age, young
children have the best 10-year graft survival with renal transplan-
tation, while adolescents and elderly people have the worst rate
of survival (Scientific Registry of Transplant Recipients, 2012).
The dose and therapeutic drug monitoring target concentrations
for immunosuppressants are extrapolated from the information
obtained in adults, and therefore most of these drugs are used
without adequate validation in children despite decades of use
for some of these drugs, such as azathioprine (Frattarelli et al.,
2014). Finally, not all immunosuppressants have liquid oral or
microgranule formulations suitable for young children. Incorrect
compounding of acceptable oral formulations for this age group,
from adult drug formulations, is a common source of error (Ali
et al., 2014).
www.frontiersin.org February 2015 | Volume 6 | Article 41 | 1
Medeiros et al. Pharmacogenomics in pediatric renal transplant
Table 1 | General differences between adult and pediatric renal transplantation.
Adults Children Implication
Main causes of end stage
renal disease
Diabetes and hypertension CAKUT and glomerulopathies Children may require urological surgery or
vesical cathetherism after transplantation.
Some glomerulopathies such as focal
segmental glomerulosclerosis have a high
rate of relapse after transplantation
Immune system Thymic atrophy
Higher expression of CD40L on T
cells
Thymic output is robust
Low expression of CD40L on T cells
Reduced T cell effector function
Higher percentage of tolerogenic dendritic
cells
Antigen presentation, T cell proliferation
and immune damage response change
with age. This can explain the better
results of graft survival in children younger
than 5 years
Drug Pharmacokinetics
and access to new drugs
Pharmacokinetics is well
characterized in adult subjects
before marketing.
New drugs can be prescribed
soon after approval
Developmental changes in absorption,
distribution, metabolism and excretion
Drugs are often prescribed off-label.
Dose and therapeutic drug monitoring are
extrapolated from adults
Young children in general require higher
doses in mg/kg than adults to achieve the
same therapeutic drug levels.
Metabolites, adverse reactions and
toxicities may be different with different
age groups, even within childhood
Viral infection risk CMV, EBV and BKV seropositive
recipients are more common
Children might be seronegative to many
viral agents
Primary infection after transplant can
make the outcome worse (i.e., graft or
patient loss, post-transplant
lymphoproliferative disease)
Living donor
10 year graft survival
65% in recipients 35–49 years
40% in recipients >65 years
80% in recipients <5 years
50% in recipients 12–17 years
Adolescents need enhanced support for
therapeutic adherence
Drug formulations of
immunosuppressants
Easy to administer, enteric coated
and extended release
formulations available
Liquid oral or microgranule formulations
are not available for all
immunosuppressants
Compounding from adult formulations is
needed, which can lead to serious errors
in dosing
PHARMACOGENOMICS IN RENAL TRANSPLANT
Pharmacogenomics offers an additional means of further indi-
vidualizing drug therapy by incorporating genetic information
to help guide safer and more effective treatment decisions.
Pharmacogenomics aims to integrate an individual’s genetic vari-
ability with the pathophysiology of disease, pharmacokinetic drug
disposition, and predicted disease outcomes to help aid in the
prediction of therapeutic efficacy and likelihood of adverse drug
reactions (Rieder and Carleton, 2014).
With regards to renal transplantation, the genetics of both the
recipient and the donor can be important for both graft and
patient outcome (Table 2). The best example in organ transplan-
tation is HLA matching between donor and recipient. Improved
HLA matching has increased graft and patient survival, reduced
the need for immunosuppression, and reduced the risk of infec-
tions and death with functioning grafts (Opelz and Dohler, 2012;
Susal and Opelz, 2013). In children, the presence of two HLA
DR mismatches increases the risk of non-Hodgkin lymphoma
by two-fold [hazard ratio (HR) of 2.04 [95% confidence inter-
val (CI) 1.11–3.74] p = 0.021] (Opelz and Dohler, 2010a). In
adults, HLA-DR mismatches are also associated to non-Hodgkin
lymphoma (HR for two mismatches = 1.56 [95% CI 1.21–1.99],
p < 0.0001) (Opelz and Dohler, 2010b) as well as osteoporosis
and hip fractures (two mismatches HR for hip fracture 2.24 [95%
CI 1.25–4.02], p = 0.007) (Opelz and Dohler, 2011).
IMMUNOSUPPRESSIVE THERAPY
Immunosuppressants used in pediatric renal transplantation are
listed in Table 2, as well the gene variants related to their ther-
apeutic effects, metabolism and transport. Many of these drugs
exhibit a narrow therapeutic index, where even small differ-
ences in dose or blood concentration may lead to serious ther-
apeutic failures and/or adverse reactions. The most common
long-term combination regimen consists of steroids, tacrolimus,
and mofetil mycophenolate (Scientific Registry of Transplant
Recipients, 2012).
GLUCOCORTICOIDS
Synthetic glucocorticoids are used as potent anti-inflammatory
and immunosuppressive agents. Part of the variability in the
response to steroids is due to genetic variation in the glucocorti-
coid signaling pathways, particularly the glucocorticoid receptor,
encoded by the NR3C1 gene and its splice variants (Koper et al.,
2014). Several genetic variations in NR3C1 have been associated
with increased glucocorticoid sensitivity (rs41423247, rs6195),
and decreased sensitivity (rs6189, rs6190, rs6198). Specifically,
the C/C genotype of rs41423247 is associated with a signifi-
cantly lower prednisolone drug bioavailability in Japanese renal
transplant recipients (Miura et al., 2009). Moreover, recently it
was found that pediatric patients with nephrotic syndrome who
carry the beta haplotype variant in the glucocorticoid receptor
Frontiers in Genetics | Pharmacogenetics and Pharmacogenomics February 2015 | Volume 6 | Article 41 | 2
Medeiros et al. Pharmacogenomics in pediatric renal transplant
Ta
b
le
2
|I
m
m
u
n
o
su
p
p
re
ss
iv
e
d
ru
g
s
u
se
d
in
p
ed
ia
tr
ic
tr
an
sp
la
n
ta
ti
o
n
an
d
ge
n
e
p
o
ly
m
o
rp
h
is
m
s
re
la
te
d
to
th
ei
r
ef
fe
ct
s,
m
et
ab
o
lis
m
,o
r
tr
an
sp
o
rt
(D
at
a
fr
o
m
o
rg
an
tr
an
sp
la
n
t/
ki
d
n
ey
d
is
ea
se
s
st
u
d
ie
s
o
n
ly
).
D
ru
g
D
es
cr
ip
ti
o
n
G
en
e/
P
ro
te
in
V
ar
ia
n
t
E
ff
ec
t
S
tu
d
y
ch
ar
ac
te
ri
st
ic
s
R
ef
er
en
ce
s
C
or
tic
os
te
ro
id
s
A
nt
i-i
nfl
am
m
at
or
y,
im
m
un
os
up
pr
es
-
sa
nt
N
R
3C
1/
gl
uc
oc
or
tic
oi
d
re
ce
pt
or
rs
41
42
32
47
In
cr
ea
se
d
gl
uc
oc
or
tic
oi
d
se
ns
iti
vi
ty
C
C
al
le
le
is
as
so
ci
at
ed
w
ith
lo
w
er
pr
ed
ni
so
lo
ne
C
m
ax
/D
os
e
(p
=
0.
02
1)
an
d
lo
w
er
A
U
C
(p
=
0.
02
9)
95
Ja
pa
ne
se
re
na
lt
ra
ns
pl
an
t
ad
ul
ts
M
iu
ra
et
al
.,
20
09
G
R
-9
β
ha
pl
ot
yp
e
ca
rr
ie
rs
In
cr
ea
se
d
in
ci
de
nc
e
of
re
la
ps
e
an
d
st
er
oi
d
de
pe
nd
en
ce
in
ch
ild
re
n
w
ith
ne
ph
ro
tic
sy
nd
ro
m
e
C
ar
rie
rs
ha
d
a
hi
gh
er
in
ci
de
nc
e
of
st
er
oi
d
de
pe
nd
en
ce
(H
R
3.
05
[9
5%
C
I1
.3
7–
6.
74
]p
=
0.
00
6)
an
d
fr
eq
ue
nt
re
la
ps
es
(H
R
1.
98
[9
5%
C
I1
.0
5–
3.
75
],
p
=
0.
03
6)
11
3
ch
ild
re
n
w
ith
ne
ph
ro
tic
sy
nd
ro
m
e.
Te
en
in
ga
et
al
.,
20
14
A
za
th
io
pr
in
e
A
nt
i-p
ro
lif
er
at
iv
e
TP
M
T
/T
hi
op
ur
in
e
m
et
hy
ltr
an
sf
er
as
e
rs
18
00
64
2
rs
18
00
46
0
rs
11
42
34
5
rs
56
16
14
02
Li
fe
-t
hr
ea
te
ni
ng
m
ye
lo
su
pp
re
ss
io
n
A
ss
oc
ia
te
d
al
le
le
s
pr
ed
ic
te
d
le
uk
op
en
ia
(O
R
4.
26
[9
5%
C
I
1.
49
–1
2.
1]
,p
=
0.
00
8)
15
7
ad
ul
t
tr
an
sp
la
nt
re
ci
pi
en
ts
w
ith
TP
M
T
de
fic
ie
nc
y
Ku
rz
aw
sk
ie
t
al
.,
20
09
M
of
et
il
M
yc
op
he
no
la
te
A
nt
i-p
ro
lif
er
at
iv
e
C
Y
P
2C
8/
C
yt
oc
hr
om
e
P
45
0
2C
8
rs
11
57
20
76
H
ig
he
r
ris
k
of
an
em
ia
,
(H
az
ar
d
ra
tio
3.
24
,9
5%
C
I
1.
7–
6.
2,
p
=
0.
00
03
7)
97
8
ad
ul
t
re
na
lt
ra
ns
pl
an
t
re
ci
pi
en
ts
Ja
co
bs
on
et
al
.,
20
11
Lo
w
er
ris
k
of
le
uk
op
en
ia
in
ca
rr
ie
rs
of
th
e
w
ild
ty
pe
ge
no
ty
pe
(G
G
vs
.G
A
H
R
0.
14
[9
5%
C
I0
.0
3–
0.
59
],
p
=
0.
00
78
3)
18
9
ad
ul
t
re
na
lt
ra
ns
pl
an
t
W
oi
lla
rd
et
al
.,
20
14
U
G
T2
B
7/
U
D
P-
gl
uc
ur
on
os
yl
-
tr
an
sf
er
as
e
2B
7
rs
74
38
13
5
In
cr
ea
se
d
ris
k
of
an
em
ia
in
G
G
vs
.A
A
(H
R
1.
88
[9
5%
C
I
1.
23
–2
.8
8]
,p
=
0.
00
3)
18
9
ad
ul
t
re
na
lt
ra
ns
pl
an
t
W
oi
lla
rd
et
al
.,
20
14
S
iro
lim
us
m
TO
R
in
hi
bi
to
r
C
Y
P
3A
4/
C
yt
oc
hr
om
e
p4
50
3A
4
rs
35
59
93
67
20
%
lo
w
er
m
et
ab
ol
ic
ra
te
in
vi
tr
o,
bu
t
no
ch
an
ge
in
ph
ar
m
ac
ok
in
et
ic
s
11
3
ad
ul
t
re
na
lt
ra
ns
pl
an
t
re
ci
pi
en
ts
sw
itc
he
d
fr
om
cy
cl
os
po
rin
e
to
si
ro
lim
us
W
oi
lla
rd
et
al
.,
20
13
(C
on
tin
ue
d)
www.frontiersin.org February 2015 | Volume 6 | Article 41 | 3
Medeiros et al. Pharmacogenomics in pediatric renal transplant
Ta
b
le
2
|C
o
n
ti
n
u
ed
D
ru
g
D
es
cr
ip
ti
o
n
G
en
e/
P
ro
te
in
V
ar
ia
n
t
E
ff
ec
t
S
tu
d
y
ch
ar
ac
te
ri
st
ic
s
R
ef
er
en
ce
s
C
yc
lo
sp
or
in
C
al
ci
ne
ur
in
in
hi
bi
to
r
C
Y
P
3A
4/
C
yt
oc
hr
om
e
p4
50
3A
4
C
Y
P
3A
5
A
B
C
B
1/
p-
gl
yc
op
ro
te
in
rs
27
40
57
4
rs
77
67
46
,
rs
10
26
42
72
rs
10
45
64
2
9%
hi
gh
er
or
al
cy
cl
os
po
rin
e
cl
ea
ra
nc
e
N
o
im
pa
ct
on
cy
cl
os
po
rin
e
ph
ar
m
ac
ok
in
et
ic
s
N
o
im
pa
ct
on
cy
cl
os
po
rin
e
ph
ar
m
ac
ok
in
et
ic
s
15
1
ad
ul
t
ki
dn
ey
an
d
he
ar
t
tr
an
sp
la
nt
re
ci
pi
en
ts
H
es
se
lin
k
et
al
.,
20
04
A
B
C
B
1/
p-
gl
yc
op
ro
te
in
rs
20
32
58
2
s1
12
85
03
1.
3–
1.
6
hi
gh
er
cy
cl
os
po
rin
e
bi
oa
va
ila
bi
lit
y
an
d
lo
w
er
pr
e-
he
pa
tic
ex
tr
ac
tio
n
ra
tio
,
on
ly
in
su
bj
ec
ts
>
8
ye
ar
s
10
4
pe
di
at
ric
re
na
lt
ra
ns
pl
an
t
re
ci
pi
en
ts
Fa
nt
a
et
al
.,
20
08
X
P
C
/X
er
od
er
m
a
pi
gm
en
to
su
m
co
m
pl
em
en
ta
tio
n
gr
ou
p
C
rs
22
28
00
1
C
yc
lo
sp
or
in
e
ne
ph
ro
to
xi
ci
ty
H
R
0.
41
[9
5%
C
I0
.2
7–
0.
63
],
p
=
0.
00
00
4
32
3
re
na
lt
ra
ns
pl
an
t
re
ci
pi
en
ts
tr
ea
te
d
w
ith
cy
cl
os
po
rin
e
an
d
69
2
tr
ea
te
d
w
ith
ta
cr
ol
im
us
Ja
co
bs
on
et
al
.,
20
12
C
Y
P
2C
9
/C
yt
oc
hr
om
e
p4
50
2C
9
rs
10
57
91
0
C
yc
lo
sp
or
in
e
ne
ph
ro
to
xi
ci
ty
H
R
3.
5
[9
5%
C
I1
.9
1–
6.
61
],
p
=
0.
00
00
6
PA
X
4/
pa
ire
d
bo
x
ge
ne
4
rs
71
27
04
C
yc
lo
sp
or
in
e
ne
ph
ro
to
xi
ci
ty
H
R
2.
09
[9
5%
C
I1
.4
5–
3.
01
],
p
=
0.
00
00
7
Ta
cr
ol
im
us
C
al
ci
ne
ur
in
in
hi
bi
to
r
C
Y
P
3A
4/
C
yt
oc
hr
om
e
p4
50
3A
4
rs
35
99
36
7
50
%
lo
w
er
ta
cr
ol
im
us
do
se
re
qu
ire
m
en
ts
in
no
n-
C
Y
P
3A
5
ex
pr
es
se
rs
12
9
ad
ul
t
re
na
lt
ra
ns
pl
an
t
re
ci
pi
en
ts
(5
9
te
st
ed
at
3
m
on
th
s,
80
te
st
ed
1–
5
ye
ar
s
af
te
r
tr
an
sp
la
nt
at
io
n)
de
Jo
ng
e
et
al
.,
20
14
C
Y
P
3A
5/
C
yt
oc
hr
om
e
p4
50
3A
5
rs
77
67
46
Ta
cr
ol
im
us
ch
ro
ni
c
to
xi
ci
ty
,
m
or
e
fr
eq
ue
nt
in
th
os
e
ex
pr
es
si
ng
th
e
en
zy
m
e,
H
R
2.
38
[9
5%
C
I1
.1
5–
4.
92
],
p
=
0.
01
30
4
ad
ul
t
re
na
lg
ra
ft
re
ci
pi
en
ts
Ku
yp
er
s
et
al
.,
20
10
Ta
cr
ol
im
us
do
se
re
qu
ire
m
en
t
is
lo
w
er
in
no
n-
C
Y
P
3A
5
ex
pr
es
se
rs
29
1
re
na
lt
ra
ns
pl
an
t
re
ci
pi
en
ts
(1
24
ad
ul
ts
,1
67
pe
di
at
ric
)
G
ar
ci
a-
R
oc
a
et
al
.,
20
12
Frontiers in Genetics | Pharmacogenetics and Pharmacogenomics February 2015 | Volume 6 | Article 41 | 4
Medeiros et al. Pharmacogenomics in pediatric renal transplant
exhibit a significantly worse outcome, with increased frequency
of first relapse, higher frequency of relapses and steroid depen-
dence (Teeninga et al., 2014). Even though there have been
significant efforts to withdraw steroids or even to avoid steroids
altogether in renal transplantation (Grenda, 2013), approximately
60% of pediatric transplant patients continue to receive steroids
(Dharnidharka et al., 2014). The most common glucocorticoid
adverse effects include cushingoid appearance, dyslipidemias,
diabetes mellitus, cataracts, hypertension, growth impairment,
osteoporosis, femoral avascular necrosis, cataracts, impaired heal-
ing and increased susceptibility to infection (Tredger et al., 2006).
Calcineurin inhibitors
Cyclosporine and tacrolimus are potent immunosuppressants
that inhibit calcineurin, a protein phosphatase involved in T cell
activation. Much of the success of renal transplantation has been
due to the introduction of cyclosporine in 1983. Tacrolimus has
now largely replaced cyclosporine in the treatment of transplant
patients, due to its enhanced potency and fewer cosmetic adverse
effects. Both share adverse events such as acute and chronic
nephrotoxicity (Issa et al., 2013), hypertension, dyslipidemia, and
increased risk of new onset diabetes mellitus (Heisel et al., 2004).
Cyclosporine also produces hirsutism and gingival hyperplasia
(Halloran, 2004).
Cyclosporine and tacrolimus metabolism depend largely upon
the liver and intestine expression of the phase I metabolizing
enzymes CYP3A4 and CYP3A5 in the liver and intestine. These
drugs are known to be transported across cell membranes by
p-glycoprotein (Table 2).
Hesselink and coworkers studied the impact of CYP3A4∗1B
(rs2740574), CYP3A5∗3 and 6 (rs776746, rs10264272), and
ABCB1 (rs1045642) on cyclosporine pharmacokinetics in 151
adult kidney and heart transplant recipients. Patients carrying the
CYP3A4∗1B variant allele exhibited a 9% increased clearance of
oral cyclosporine; while none of the other studied variants influ-
enced cyclosporine pharmacokinetics (Hesselink et al., 2004). In
a study of 104 pediatric renal transplant recipients (0.36–16.3
years), Fanta et al, examined the potential role of genetic varia-
tions in ABCB1, CYP3A4, CYP3A5, and SLCO1B1 in cyclosporine
pharmacokinetics. Interestingly, genetic factors were found to
affect the bioavailability only in patients older than 8 years of
age, specifically those carrying the ABCB1 variants rs1128503,
rs2032582, had 1.3–1.6 higher cyclosporine bioavailability and
lower pre-hepatic extraction ratio than non-carriers, but no sig-
nificant differences were observed in subjects younger than 8
years. The authors suggest that developmental changes may con-
found the effect of genetic factors, therefore questioning the
value of pharmacogenetic testing in young children (Fanta et al.,
2008). Further studies in young children will help to better define
the role of ontogeny on the utility of these pharmacogenetic
biomarkers.
For tacrolimus, the CYP3A5 gene polymorphism rs776746 has
been associated with lower dose requirements and bioavailabil-
ity in both adults and children. This variant causes a loss of
CYP3A5 activity due to a splice site variant leading to a trun-
cated, inactive enzyme. Interestingly, this association appears to
be independent of the tacrolimus formulation (Jacobo-Cabral
et al., 2014). The allelic frequency changes with ethnicity, 70–80%
of African Americans express the enzyme, in contrast to 5–15% of
Caucasians, 30% of Asians and 50% of Mexicans (Garcia-Roca
et al., 2012). Nevertheless, the variant has not been associated
with acute rejection, probably because transplant patients end-up
achieving target concentrations of tacrolimus thanks to therapeu-
tic drugmonitoring and closemonitoring overall (Hesselink et al.,
2008).
In a prospective study, adult patients were randomized to
receive tacrolimus either according to standard protocol, or based
on CYP3A5 genotype to guide dosing decisions. Dosing by geno-
type acquired tacrolimus target concentrations 75%more rapidly
and with fewer dose modifications. On day 3 of tacrolimus ther-
apy, 43% of those patients whose therapy was guided by genotype
had reached target trough concentrations in contrast to 29% who
received standard treatment (Thervet et al., 2010). Nevertheless,
the impact of obtaining target tacrolimus concentrations sooner
on longitudinal outcomes such as graft survival or rejection
episodes has not been reported. Kuypers et al. reported that renal
transplant patients expressing CYP3A5 who require higher doses
to achieve therapeutic trough concentrations have a higher risk of
chronic nephrotoxicity (HR 2.38 [95% CI 1.15–4.92]) (Kuypers
et al., 2010).
Jacobson et al. studied early nephrotoxicity during the first
6 months post-transplant in 323 renal recipients treated with
cyclosporine or tacrolimus. Nephrotoxicity was defined as a rise
in serum creatinine that responded to the reduction or discontin-
uation of the calcineurin inhibitor. Nephrotoxicity was observed
in 22.6% of cyclosporine and 19.8% of tacrolimus treated patients
respectively. Interestingly, gene polymorphisms in XNC, CYP2C9
and PAX4 were associated with cyclosporine nephrotoxicity, but
not with tacrolimus toxicity (Table 2) (Jacobson et al., 2012).
Residual variability can also be attributed to other gene
polymorphisms, such as CYP3A4∗22 (rs35599367) that reduces
CYP3A4 activity by 20% (Elens et al., 2011), and leads to 50%
lower tacrolimus dose requirements in patients with concurrent
non-expression of CYP3A5 (de Jonge et al., 2014).
In addition, the role of ABCB1 remains unclear. There are con-
troversial studies about the impact of ABCB1 (p-glycoprotein)
genes on the pharmacokinetics of tacrolimus, due to the impor-
tance of the transporter in the absorption, distribution and elimi-
nation of drugs, but its overall effect on tacrolimus bioavailability
appears to be small (Mai et al., 2004; Hesselink et al., 2014).
Antiproliferatives
Azathioprine. The only immunosuppressant used in transplan-
tation that has an FDA-approved drug label with pharmaco-
genetic information is azathioprine. Nevertheless, its use has
declined over the past decade due to the substitution of mycophe-
nolate mophetil in post transplant immunosuppression regi-
mens. Azathioprine is still used in patients who exhibit severe
adverse effects from mycophenolate mofetil, and in some coun-
tries where the price of mycophenolate mofetil is prohibitive
(Bansal et al., 2011). Azathioprine is a prodrug, rapidly con-
verted to 6-mercaptopurine, which is further converted cytotoxic
thioguanine nucleotides by hypoxanthine-guanine phosphoribo-
syltransferase and a series of enzymatic process including kinases.
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The thioguanine nucleotides reduce inflammation by inhibiting
DNA replication and blocking CD28 costimulatory signaling via
RAC1. Excess thioguanine nucleotides induce myelosupression
and are inactivated by the enzyme thiopurine methyltransferase
(TPMT) to methylcaptopurine nucleotide. To date, 37 variants
in TPMT alleles have been identified (Roberts et al., 2014).
The polymorphisms in TPMT that affect azathiopurine toxicity
are related to the activity of the enzyme. Approximately 0.3 to
1% of patients of European ancestry inherit two non-functional
TPMT alleles (homozygous) for low or absent TMPT activity
(also called poor methylators), and 10% inherit a single non-
functional allele and exhibit intermediate enzyme activity and
have 90% normal activity. Poor methylators are at risk of devel-
oping severe life-threatening myelotoxicity if they receive azathio-
prine (Weinshilboum and Sladek, 1980). Therefore, genotyping
or phenotyping by measuring TPMT activity is recommended to
identify patients at risk. Nearly 95% of poor TPMT methylation
is due to four alleles TMPT∗2 (238 G>C, rs1800462), TMPT3∗A
(460G>A rs1800460; 719 A>G rs1142345),TPMT∗3C (719 A>G
rs1142345) and TMPT∗8 (644G>A, rs56161402). There is sig-
nificant interethnic variability in the frequency of these alleles
(Roberts et al., 2014). Kurzawski et al evaluated themost common
variants in 157 renal transplant recipients, and variant carriers
had higher risk of leukopenia (OR 4.26 [95% CI 1.49–12.1],
p = 0.008) (Kurzawski et al., 2009).
Mycophenolic acid. Mycophenolic acid is an inhibitor of ino-
sine 5-monophosphate dehydrogenase (IMPDH), a key enzyme
responsible for the de novo pathway of guanosine nucleotide syn-
thesis in B and T lymphocytes. Inhibition of IMPDH thus us
reduces cell proliferation and suppresses antibody formation and
cell-mediated immune responses, which are key factors in graft
rejection. Mycophenolic acid was approved by the FDA to pre-
vent transplant rejection in 1995. For children, a pediatric oral
solution is available in some countries. Mycophenolate mofetil
is a prodrug (2, 4- morpholinoethylester of mycophenolic acid)
that is hydrolyzed by esterases in gastrointestinal tract, blood and
liver into the active drug mycophenolic acid. This is subsequently
metabolized by the uridine diphosphate-glucuronosyltransferase
enzymes (UGT), primarily UGT1A9 in the liver and UGT1A8
in the intestine to a stable, inactive phenolic glucuronide. The
UGT2B7 produces a mycophenolate-acyl-glucoronide but the
effect on inhibition of IMPDH is minimal compared to mycophe-
nolic acid (Gensburger et al., 2009). Adverse effects include ane-
mia, leukopenia and gastrointestinal adverse effects that can lead
to dose reduction and low drug exposure concentrations with
the consequent risk of acute rejection episodes or graft failure.
An enteric-coated formulation of mycophenolic acid is available
as mycophenolate sodium, and conversion to equimolar doses of
mycophenolate mofetil to enteric-coated mycophenolic acid leads
to similar bioavalability in children (Reyes et al., 2010). There
is a high int-ra and interpatient variability in the bioavailabil-
ity of mycophenolic acid, and since it undergoes enterohepatic
recirculation, more than one peak can be observed after oral
administration (Filler, 2006; Reyes et al., 2010).
In a study including 978 adult renal transplant recipients
treated with mycophenolate mofetil, anemia occurred in 9.5%
and leukopenia in 22.9% of patients. CYP2C8 rs11572076 was
associated with the risk of anemia (HR 3.4 [95% CI 1.7–6.20],
p = 00037), as was IL12A rs568408 (HR 1.98 [95% CI 1.39–
2.82], p = 0.00014) and HUS1 rs2037483 (HR 0.54 [95% CI
0.39–0.74], p = 0.00016). These variants were not associated with
the risk of leukopenia (Jacobson et al., 2011). A recent study
by Woillard et al in 189 renal transplant adults treated with
enteric-coated mycophenolic acid, in whom 15 SNPs were stud-
ied (in IMPDH1, IMPDH2, ABCC2, SLCO1B3, CYP2C8, HUS1,
UGT1A8,UGT1A9,UGT2B27, IL12A), the variant alleleUGT2B7
(840 G>A rs7438135) was associated with an increased risk of
anemia (GG vs. AA HR 1.8 [95% CI 1.23–2.88], p = 0.0034).
In the same study, CYP2C8 rs11572076 wild type was associated
with a lower risk of leukopenia (HR 0.14 [95% CI 0.03–0.59],
p = 0.0078), but not with anemia. The authors did not find any
of the studied variants associated with diarrhea or biopsy-proven
acute rejection (Woillard et al., 2014).
mTOR inhibitors. Sirolimus (also known as rapamycin) is an
inhibitor of mammalian target of rapamycin (mTOR) and the
activation of the cell cycle. Specifically, it prevents the genera-
tion of the coestimulatory signal during G0–G1 in lymphocytes,
and the post-transduction events after cytokine stimulation of
G1 (Stenton et al., 2005). This drug was approved by the FDA
in 1999 to prevent acute rejection in renal transplant recipi-
ents. It is metabolized by CYP3A and it is also a substrate for
p-glycoprotein. Liquid and solid oral formulations are available.
As with other immunosuppressants, it exhibits a high intra-
and inter-patient variability in pharmacokinetics, and therapeu-
tic drug monitoring is recommended. Adverse effects include
hyperlipidemia, thromocytopenia, peripheral edema, dermatitis
and impaired wound healing (Halloran, 2004; Tredger et al.,
2006).
There are controversial results in studies about the relevance
of gene polymorphisms in CYP3A and ABCB1 (p-glycoprotein),
pharmacokinetics and outcome. Woillard et al. studied 113
renal transplant adults switched from a calcineurin inhibitor to
sirolimus. They genotyped patients forCYP3A4∗22 (rs35599367),
CYP3A5∗3 (rs776746), POR (p450 oxidoreductase, rs1057868),
and PPARA (Peroxisome proliferator activated receptor alpha,
rs4253728). Patients with CYP3A4∗22 had a 20% lower sirolimus
metabolic rate in vitro, but no differences were observed in the
pharmacokinetics or the frequency of adverse effects (Woillard
et al., 2013).
RECIPIENT GENOTYPE AND RISK OF ACUTE REJECTION
The progress in the field of pediatric transplantation has reduced
the 1-year acute rejection rate from 55% in late 1980’s to 15%
today (Dharnidharka et al., 2014). Even when successfully treated,
acute rejection reduces the survival rate of the graft (Rusai and
Szabo, 2014).
There are controversies regarding the association between
gene polymorphisms and acute rejection. It has been postu-
lated that the basal production of cytokines, probably determined
genetically can be related to the risk of rejection (Goldfarb-
Rumyantzev and Naiman, 2010), nevertheless most of the studies
have been performed in small sample populations, not corrected
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for multiple testing, and importantly, without replication in an
independent cohort (Phelan et al., 2014).
Recently, a study reported significant associations with vari-
ants in the toll-like receptor gene TLR4 (rs498670, rs4986791).
In a cohort of 238 renal transplant recipients, those patients with
the TLR4 variants were less likely to have acute rejection (RR 0.41,
[95% CI 0.21–0.93], p = 0.001) but more prone to severe bacte-
rial infections (RR 1.33, [95% CI 1.12–1.67], p = 0.01) (Ducloux
et al., 2005). The authors postulated that since TLR4 pathway is
crucial for alloreactive responses and can be activated by endoge-
nous ligands and pathogen associated recognition patterns, the
determination of TLR4 genotype could be used to modulate de
immunosuppressive treatment and optimize the monitoring and
prophylaxis of post-transplant infections.
Chen and coworkers studied the genetic polymorphisms in
IL-2 (rs 2069762), IL-10 (−592 C>A and −1082 G>A), TGF-
β1 (915 G>C) and IL2-RB (rs228942 and rs228953) in 325 renal
transplant recipients 1 year after surgery. However, these variants
did not exhibit significant associations with acute rejection (Chen
et al., 2014).
To the best of our knowledge, there are no pediatric stud-
ies looking at genetic factors that contribute to the risk of acute
rejection.
DONOR GENOTYPE AND TRANSPLANT OUTCOMES
The ABCB1donor genotype rs1045642 has been associated with
long-term graft survival, as reported by Moore et al in a dis-
covery cohort of 811 adult transplant recipients (HR 1.69, [95%
CI 1.2–2.40], p = 0.003), and further validated in 675 donors
from Belfast (HR 1.68, [95% CI 1.21–2.32], p = 0.002) and in
2985 donors from a Collaborative Transplant Study (HR 1.84,
[95% CI 1.08–3.13], p = 0.006), since the variant is related to p-
glycoprotein expression it might play a role in the development
of calcineurin inhibitor nephrotoxicity and fibrosis (Moore et al.,
2012).
Apolipoprotein gene (APOL1) variants rs73885319 and
rs71785313 have been associated with kidney disease while
conferring protection against Trypanosoma brucei rhodesiense.
African Americans with the risk variants have higher odds
of developing end stage renal disease due to focal segmental
glomeruloesclerosis (OR 10.5, 95% CI 6.0–18.4) or hypertension
(OR 7.3, 95% CI 5.6–9.5) (Genovese et al., 2010). In regard to
transplant patients, one study with a mean follow up of 26.4
months suggested that kidneys from deceased donors with two
APOL1 risk variants had significantly shorter graft survival (HR
3.84, p = 0.008) (Reeves-Daniel et al., 2011) whereas in the case
of the receptors, carrying two risk variants alleles do not increase
the risk of 5 year allograft loss (HR 0.96, [95% CI 0.61–1.48],
p = 0.84).
NEW TECHNOLOGIES
There are few reports using genome wide association studies
(GWAS) in renal transplantation. O’ Brian et al. recently exam-
ined the genetic factors associated with graft function at 5 and
10 years post-transplant in a GWAS of 326 adult Irish donor
transplant recipients. After correcting for multiple testing, two
variants were significantly associated with 5-year creatinine levels,
including rs6565887, a non-coding intronic variant in the zinc
finger protein 516 gene (ZNF516), which is expressed mainly in
lungs, spleen and kidney (p = 4.04e-08); and rs3811321, in a
non-coding exon of the T-cell receptor alpha chain gene (TCRA)
(p = 7.63 × 10e-08). Together these variants accounted for up to
17.4% of trait variance. These variants were predictors of 10-year
allograft survival (rs3811321: 70% vs. 30%, incidence ratio 2.4
p = 0.004, rs6565887: 70% vs. 45%, incidence ratio 1.7, and
p = 0.025). Importantly, these findings still need independent
replication (O’Brien et al., 2013).
GWAS was recently used to identify genetic variants related to
new onset diabetes after transplantation in adult renal transplant
recipients. From a study of 26 cases and 230 controls, 26 SNPs
were associated with new onset diabetes. These associations were
replicated for eight of the SNPs by follow-up genotyping of a sec-
ond cohort of patients, 57 cases and 383 controls. These variants
included ATP5F1P6 rs10484821 encoding an inferred mitochon-
drial ATP synthase pseudogene (OR 3.5 [95% CI 2.1–5.8], p =
1.5 × 10−7); DNAJC16 rs7533125 whose transcript is part of the
heat shock protein 40 complex (OR 2.4 [95% CI 1.5–3.6], p =
0.001), CELA2B rs2861484 encoding a pancreatic chymotrypsin-
like elastase (OR 2.4 [95% CI 1.5–3.7], p = 0.0001); AGMAT
rs11580170 encoding agmantine, a protein scavenger of reactive
oxygen species to protect the mitochondrial membrane (OR 2.2
[95% CI 1.4–3.4], p < 0.00), CASP9 rs2020902 in the caspase 9
gene (OR 2.3 [95% CI 1.5–3.6], p < 0.001); NOX4 rs1836882
that encodes an enzyme of the NAPDH oxidase complex (OR
2.7 [95% CI 1.5–4.8], p = 0.001) and NPPA rs198372, natri-
uretic peptide precursor A (OR 2.5 [95% CI 1.5–4.2], p < 0.001)
(McCaughan et al., 2014).
It has been pointed out that outcomes such as patient and graft
survival are complex and likely incorporate the effects of many
genes. Studies need to be sufficiently powered to avoid type II
errors (false negatives), since significant associations are difficult
to demonstrate if the sample size is too small or the SNP is rare in
the studied population (Stegall et al., 2014).
Recently, the use of mRNA gene expression analysis of urinary
cells has been proposed as a non-invasive and sensitive method to
diagnose acute rejection. The use of a three gene molecular signa-
ture (IP10, CD3ε and 18s rRNA) was able to discriminate between
rejecting and non-rejecting samples (area under the curve [AUC]
of the receiver operating curve analysis [ROC] of 0.85, 95% CI
0.78–0.91, p < 0.001) (Suthanthiran et al., 2013).
The peripheral blood gene expression by quantitative real-
time PCR was used to diagnose acute transplant rejection
using a 17-gene set (kidney solid organ response test, kSORT).
The study was validated in both adult and pediatric recipi-
ents, and accurately indicated the risk and prevalence of acute
rejection in 558 transplant recipient samples (final AUC 0.92,
95% CI 0.86–0.98). Further studies are needed to replicate
this finding and to determine if kSORT can be used serially
post-transplant to stratify patient immune risk, adjust medi-
cations, or decide the requirement for biopsy (Roedder et al.,
2014).
There is a need for pharmacogenomics studies in children,
since ontogeny may modify the relationship between genotype-
phenotype including the profile of adverse events (Hines, 2008).
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